{"title":"AbbVie Licenses Phase II-Ready Antibody Programme to Receptos for Development in Eosinophilic Oesophagitis","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I4.1914","DOIUrl":null,"url":null,"abstract":"Abbott spin-off AbbVie has licensed a deprioritised antibody programme to Receptos as part of a risk-sharing deal that allows the big pharma company to opt back into development and commercialisation of the drug candidate should it demonstrate proof-of-concept in the treatment of the orphan disease eosinophilic oesophagitis. ABT-308, a humanised anti-interleukin-13 (IL-13) monoclonal antibody that has been designated RPC4046 by Receptos, was well tolerated in a Phase I study in healthy volunteers and patients with mild-to-moderate persistent asthma.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"2013 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I4.1914","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Abbott spin-off AbbVie has licensed a deprioritised antibody programme to Receptos as part of a risk-sharing deal that allows the big pharma company to opt back into development and commercialisation of the drug candidate should it demonstrate proof-of-concept in the treatment of the orphan disease eosinophilic oesophagitis. ABT-308, a humanised anti-interleukin-13 (IL-13) monoclonal antibody that has been designated RPC4046 by Receptos, was well tolerated in a Phase I study in healthy volunteers and patients with mild-to-moderate persistent asthma.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
